At the news
? NEUTRALIMPACT 6/10 8-K filed Nov 9, 2026 at 08:15 ET
Heron Therapeutics reported Q3 2026 net revenue of $35.3M, down 7.8% YoY from $38.2M, with the Oncology franchise declining 22.2% (CINVANTI -16.6%, SUSTOL sales ceased). The company announced a definitive asset purchase agreement under which CorMedix Therapeutics will acquire substantially all of Heron's assets, subject to stockholder approval.
- Q3 2026 net revenue of $35.3M, down 7.8% from $38.2M in Q3 2025
- Acute Care franchise revenue up 22.5% YoY to $15.1M
- Oncology franchise revenue down 22.2% YoY to $20.1M
- CINVANTI revenue down 16.6% YoY to $20.0M
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access